A court in India has reportedly removed a stay on the merger between pharmaceutical giants Sun Pharmaceutical and Ranbaxy after allegations surfaced of insider trading.

The $3.2 billion merger was put on hold after a group of investors filed to have an investigation launched into the merger, claiming insider trading had …read more

Source: Global Competition Law Blogs